2024-11-13 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**Company Overview:** Johnson & Johnson is a multinational healthcare conglomerate that develops and sells a wide range of pharmaceutical products, medical devices, and consumer healthcare products.

**1. Performance Comparison with S&P 500:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 45.2% | 9.1% | 6.8% | 0.7 | 336.4 |
| 2016-2018  | 39.2% | 16.9% | 6.9% | 0.7 | 310.7 |
| 2017-2019  | 36.4% | 16.9% | -15.3% | 0.7 | 351.2 |
| 2018-2020  | 22.6% | 27.1% | -24.7% | 0.7 | 378.9 |
| 2019-2021  | 45.0% | 27.1% | -55.0% | 0.6 | 411.9 |
| 2020-2022  | 30.8% | 27.1% | 7.2% | 0.5 | 425.3 |
| 2021-2023  | 8.6% | 15.2% | -26.4% | 0.3 | 377.4 |
| 2022-2024  | -3.7% | 15.2% | -34.2% | 0.2 | 373.3 |

* JNJ's cumulative return is 57.42% compared to the S&P 500's 179.55%.
* JNJ significantly underperformed the S&P 500 by 122.13%, placing it at the bottom 0% of its historical performance range. 
* JNJ exhibits a Beta of 0.2, suggesting a lower sensitivity to market movements compared to the broader market.
* The Alpha is consistently negative, indicating that JNJ has underperformed its benchmark index.

**2. Recent Price Movement:**

* Closing price: 152.58
* 5-day Moving Average: 155.54
* 20-day Moving Average: 160.36
* 60-day Moving Average: 162.26

JNJ is currently trading below all three moving averages, indicating a short-term downtrend.

**3. Technical Indicators:**

* **RSI:** 9.81 -  Significantly oversold, suggesting potential for a bounce back.
* **PPO:** -0.52 -  Negative PPO suggests a downtrend, but oversold RSI indicates potential for a reversal.
* **Delta_Previous_Relative_Divergence:** -7.24 -  Indicates a recent short-term decline in relative performance.
* **Expected Return:** 0.0% - This suggests that JNJ is not expected to outperform the S&P 500 in the long term (over 2 years). 

**4. Recent Earnings & Forecast:**

| Date        | EPS     | Revenue        |
|-------------|---------|----------------|
| 2024-10-23  | 1.12    | 22.47 B$       |
| 2024-07-25  | 1.95    | 22.45 B$       |
| 2024-05-01  | 1.35    | 21.38 B$       |
| 2024-02-16  | 1.68    | 21.39 B$       |
| 2023-10-27  | 10.32   | 21.35 B$       |

* The most recent earnings release (2024-10-23) showed EPS of 1.12, which was slightly below analysts' estimates. 
* Revenue remains relatively consistent, but EPS has been volatile in recent quarters.
* It's crucial to monitor future earnings releases and analyst forecasts to gauge the future trajectory of JNJ's performance.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2024-09-30  | $22.47B   | 69.01%       |
| 2024-06-30  | $22.45B   | 69.40%       |
| 2024-03-31  | $21.38B   | 69.55%       |
| 2023-12-31  | $21.39B   | 68.23%       |
| 2023-09-30  | $21.35B   | 69.06%       |

* JNJ exhibits a consistently high profit margin, showcasing its strong profitability and ability to manage expenses effectively.
* Steady revenue growth indicates a healthy business model and resilience in the face of market fluctuations.

**2) Capital and Profitability:**

| Quarter      | Equity   | ROE    |
|--------------|----------|--------|
| 2024-09-30  | $70.16B | 3.84% |
| 2024-06-30  | $71.54B | 6.55% |
| 2024-03-31  | $70.02B | 4.65% |
| 2023-12-31  | $68.77B | 5.89% |
| 2023-09-30  | $71.23B | 36.54% |

* JNJ holds a substantial amount of equity, demonstrating its financial stability and strong capital position. 
* ROE, while fluctuating, reflects a consistent ability to generate profits from its capital base.

**6. News & Recent Issues:**

* Recent earnings release was met with mixed reactions, with some analysts highlighting concerns regarding EPS growth and the impact of the global economic landscape.
* The company continues to face legal challenges related to its talcum powder products, which could potentially impact future earnings.
* JNJ is also actively involved in acquisitions and divestitures, aiming to expand its product portfolio and optimize its business structure.

**7. Recent Market Outlook, Analyst Opinions & Performance Highlights:**

* **Recent Market Outlook:** JNJ's stock has been experiencing a volatile period, with investors exhibiting cautious sentiment due to concerns regarding earnings growth and potential legal liabilities. However, some analysts believe that JNJ's strong dividend and stable business model offer attractive long-term investment opportunities.
* **Analyst Opinions:** Analyst ratings are mixed, with some offering buy or hold recommendations, while others are more cautious, with some issuing sell ratings. 
* **Performance Highlights:** Despite recent underperformance, JNJ remains a dominant player in the healthcare industry, with a long track record of success and a strong brand reputation. Its diversified portfolio and commitment to innovation are key strengths for the future.

**8. Overall Analysis:**

JNJ is a large-cap, dividend-paying company with a strong brand and long-term track record. While recent performance has been underwhelming and concerns remain regarding legal liabilities, its strong financial position and stable business model offer potential for long-term growth. However, investors should closely monitor earnings releases, analyst opinions, and news developments to make informed investment decisions. 

**9. Key Takeaways:**

* JNJ significantly underperformed the S&P 500 in recent years. 
* The stock is currently trading below its moving averages, indicating a short-term downtrend.
* Technical indicators suggest oversold conditions, which could lead to a potential bounce back.
* JNJ remains a profitable company with a strong capital position, but recent earnings growth has been volatile.
* JNJ is facing legal challenges, which could impact future performance.
* While JNJ is not expected to outperform the S&P 500 in the long term, its dividend and stable business model offer long-term investment opportunities for investors with a high risk tolerance.

**Disclaimer:** This is a general analysis and should not be considered investment advice. Always conduct your own research and consult with a financial advisor before making any investment decisions. 
